UnicoCell Biomed Co., Ltd. (TPE:6794)
Taiwan
· Delayed Price · Currency is TWD 82.30
+0.30 (0.37%)
Mar 10, 2026, 1:06 PM CST
UnicoCell Biomed Company Description
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan.
The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank.
In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests.
UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.
UnicoCell Biomed Co., Ltd.
| Country | Taiwan |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Yi-Pei Hung |
Contact Details
Address: No. 13-20, Minquan East Road Taipei, 11494 Taiwan | |
| Phone | 886 2 2792 2699 |
| Website | unicocell.com |
Stock Details
| Ticker Symbol | 6794 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006794001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yi-Pei Hung | General Manager |
| Pei-Lin Chen | Chief Financial Officer, Accounting Officer and Corporate Governance Officer |
| Lin Chen-Yu | Assistant Vice President |
| Ting Wang | Assistant Vice President |
| Jui-Yu Liu | Chief Internal Auditor |